3 citations
,
October 1994 in “Journal of Dermatological Science” This study developed a novel monoclonal antibody, TYHF-1, which specifically reacts with hair keratins but not with epidermal keratins or various other tissue cells.
1 citations
,
May 2024 in “Dermatology and Therapy” This review article examines the current understanding of frontal fibrosing alopecia, noting its prevalence in different demographics and the roles of genetic and environmental factors in its pathogenesis, while highlighting that treatment approaches remain varied and lack standardization.
15 citations
,
February 2021 in “Scientific Reports” This study found that novel RNA aptamers specifically inhibited FGF5-induced cell proliferation, suggesting their potential as candidates for treating FGF5-related diseases or hair disorders.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.
September 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” In this study, freezing gamma-irradiated amniotic fluid increased hair follicles and accelerated the transition to the anagen stage in rats, suggesting potential for treating hair loss safely and effectively.
December 2020 in “TURKDERM” This case report describes a 3-year-old boy diagnosed with temporal triangular alopecia, emphasizing the importance of clinical and dermoscopic examination for correct diagnosis due to the condition's rarity and risk of misdiagnosis.
October 2025 in “International Journal of Risk & Safety in Medicine” In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.
January 2007 in “Frontiers in Medicine” This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.
53 citations
,
June 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study observed that abnormal hormone levels were associated with lower disease activity in frontal fibrosing alopecia, while thyroid disorders were a common comorbidity among the affected population.
November 1968 in “Journal of the American Pharmaceutical Association” This study reported that prompt diagnosis and treatment with 5-alpha-reductase inhibitors and topical immunomodulators are key to mitigating the effects of frontal fibrosing alopecia and preventing permanent hair loss.
October 2023 in “CRC Press eBooks” This chapter provides an overview of 11 common hair and nail conditions in children with brown skin, utilizing clinical photographs and a question-and-answer format to discuss conditions such as alopecia areata, telogen effluvium, and nail lichen planus.
February 2026 in “Indian Journal of Dermatology” This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.
32 citations
,
July 2017 in “Oncotarget” This study found that intermittent treatment with FTI lonafarnib and sulforaphane may be a promising therapeutic approach for children with Hutchinson-Gilford progeria syndrome, as it improved the cellular phenotype.
This study found that TLR2 and its ligand CEP are crucial for maintaining hair follicle health and stimulating hair growth, with deficiencies observed in aging and obesity potentially reducing regeneration.
6 citations
,
March 2009 in “Journal of the European Academy of Dermatology and Venereology” This study found no increased frequency of the TNF2 allele in Mexican patients with adverse cutaneous drug reactions mediated by delayed hypersensitivity, suggesting its lower relevance compared to findings in Caucasian populations.
June 2026 in “Indian Dermatology Online Journal” In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.
October 2024 in “Journal of Pakistan Association of Dermatologists” This study reports that a 21-year-old male with alopecia totalis responded positively to the JAK inhibitor tofacitinib, achieving complete hair regrowth after six months of treatment without significant side effects, though further research is needed to evaluate long-term efficacy.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
2 citations
,
March 2023 in “Skin research and technology” This study observed that temporal triangular alopecia in infants presents with distinct clinical and dermatoscopic features, indicating the usefulness of dermatoscopy for diagnosis and differential diagnosis.
10 citations
,
May 2019 in “BMC Complementary and Alternative Medicine” This study found that Bacillus/Trapa japonica fruit ferment filtrate extracts enhanced human hair follicle dermal papilla cell proliferation through the Akt/ERK/GSK-3β signaling pathway, suggesting potential benefits for alopecia treatment.
In this case report, the authors observed that onabotulinum toxin A therapy, extended to areas around traumatic excoriations and alopecia, resulted in notable healing and hair regrowth in a patient with trigeminal trophic syndrome and trichotillomania.
October 2025 in “Biomedicines” This study suggests that Terminalia chebula fruit extract may promote hair growth in androgenetic alopecia by activating specific signaling pathways and inhibiting 5α-reductase, showing effectiveness comparable to finasteride.
This study found that tenuazonic acid from Alternaria alternata can cause significant damage to vital organs in mice at low doses and highlights the need for regulatory measures to manage its risk in agricultural products.
July 2018 in “Elsevier eBooks” This chapter reviews traction alopecia, discusses its clinical presentation and severity grading, and reports no new clinical results; the authors highlight controversies in its treatment and prevention strategies.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.
134 citations
,
June 2012 in “International Journal of Oral and Maxillofacial Surgery” This article discusses current methods in facial feminization surgery for transsexual women and reports no new clinical results, focusing instead on various surgical techniques used to feminize facial features.
June 2025 in “British Journal of Dermatology” This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.
8 citations
,
August 2007 in “Histopathology” This article discusses the kinetic and topographical heterogeneity in follicular thyroid neoplasms and reports no new research findings; the authors emphasize understanding diverse growth patterns.
7 citations
,
January 2014 in “Case reports in pediatrics” This report discusses a case of hair toe tourniquet syndrome in an infant and emphasizes the importance of early diagnosis and treatment to prevent severe complications.